Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Sutro Biopharma (STRO) over the last 8 years, with Q3 2025 value amounting to $2.3 million.

  • Sutro Biopharma's Gains from Sales and Divestitures rose 4525.77% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 4525.77%. This contributed to the annual value of $1.7 million for FY2024, which is 4667.61% up from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Gains from Sales and Divestitures is $2.3 million, which was up 4525.77% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Gains from Sales and Divestitures registered a high of $2.3 million during Q3 2025, and its lowest value of $147349.0 during Q1 2021.
  • For the 5-year period, Sutro Biopharma's Gains from Sales and Divestitures averaged around $972374.6, with its median value being $896269.0 (2023).
  • As far as peak fluctuations go, Sutro Biopharma's Gains from Sales and Divestitures skyrocketed by 26585.71% in 2021, and later soared by 3011.88% in 2025.
  • Over the past 5 years, Sutro Biopharma's Gains from Sales and Divestitures (Quarter) stood at $238724.0 in 2021, then skyrocketed by 159.99% to $620647.0 in 2022, then skyrocketed by 86.2% to $1.2 million in 2023, then skyrocketed by 46.68% to $1.7 million in 2024, then surged by 33.26% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.0 million for Q2 2025, and $1.6 million during Q1 2025.